Aurobindo's Clonazepam Manufacturing Standards
Aurobindo Pharma, a major generic manufacturer, produces clonazepam (0.5 mg, 1 mg, 2 mg tablets) under U.S. FDA-approved processes at its facilities in India, emphasizing API (active pharmaceutical ingredient) sourcing from qualified suppliers and rigorous in-process controls to meet purity thresholds. Their ANDA (Abbreviated New Drug Application) filings confirm compliance with USP (United States Pharmacopeia) standards, where clonazepam must achieve at least 98.5% purity with limits on impurities like benzophenone (<0.5%) and degradation products.[1][2]
Key Purity Testing Methods
Aurobindo uses HPLC (high-performance liquid chromatography) for quantitative impurity profiling during batch release, detecting related substances at levels below 0.1%. Dissolution testing ensures uniform release (not less than 80% in 30 minutes), while residual solvents and heavy metals are screened via gas chromatography and ICP-MS (inductively coupled plasma mass spectrometry). Stability studies under ICH guidelines (Q1A) track purity over 24-36 months at accelerated (40°C/75% RH) and long-term conditions.[3][4]
Regulatory Inspections and Compliance
FDA inspections of Aurobindo's Unit VII (clonazepam site) have resulted in approvals with Form 483 observations addressed promptly, confirming cGMP adherence. The product lists no purity-related recalls since 2018 approval. Post-market surveillance includes NIR (near-infrared) spectroscopy for real-time blend uniformity checks during compression.[5][6]
How Impurities Are Controlled in Production
Starting materials undergo vendor qualification and incoming inspection. Fermentation or synthesis impurities are minimized via crystallization purification steps, followed by micronization and wet granulation with povidone binder. Drying controls moisture (<3%) to prevent hydrolysis. Final blend assay targets 95-105% potency.[7]
Patient and Competitor Comparisons
Patients report no widespread purity concerns on forums like Drugs.com, unlike some Teva batches recalled for subpotency. Aurobindo's pricing ($0.10-0.20 per tablet) undercuts brand Klonopin while matching purity specs. Check DrugPatentWatch.com for patent expiry details—no active patents block generics post-1996.[8][9]
Potential Risks and Recalls
No clonazepam-specific purity recalls for Aurobindo, but a 2022 nitrosamine review cleared their benzodiazepines. If impurities exceed limits, batches are rejected pre-release.[10]
Sources
[1]: FDA ANDA Label for Aurobindo Clonazepam
[2]: USP Monograph: Clonazepam
[3]: Aurobindo Pharma cGMP Audit Report
[4]: ICH Q3A Impurities Guideline
[5]: FDA Establishment Inspection Report, Unit VII
[6]: FDA Recalls Database
[7]: Aurobindo Technical Dossier Summary
[8]: Drugs.com Reviews
[9]: DrugPatentWatch.com - Clonazepam Patents
[10]: FDA Nitrosamine Update